May 13, 2025 –BIK Therapeutics, a South Korean biotech company pioneering next-generation oncology therapies, has entered a strategic collaboration with Medicilon to accelerate preclinical development of its lead candidates. Under the agreement, Medicilon will provide BIK Therapeutics with integrated preclinical research services, including pharmacokinetics, toxicology, and oncology pharmacology research. This includes key studies such as the U87-MG-luc orthotopic model and U87-MG S.C. xenograft model, aiming to accelerate the R&D of innovative oncology drugs and assist in completing IND filings.

The signing ceremony was attended by key representatives from both companies, including Jaeho Jung (CDO & VP), Kideok Shin (Director of R&D Center) of BIK Therapeutics, and Jianglin Hu (Co-CEO & CSO), Renzhong Xie (VP of Toxicology Research Department), Hanjun Zou (Executive Director of Toxicology Research Department) of Medicilon.

Complementary Strengths for Oncology Drug Development.

Founded in 2009, BIK Therapeutics has established proprietary drug R&D systems and technology platforms such as its ELiTE-DDS (drug delivery system). The company has strategically evolved from a radiopharmaceutical developer to a therapeutic innovator, focusing on biomarker-driven anti-tumor drugs.

Medicilon, as a one-stop preclinical R&D service platform, offers comprehensive evaluation services for oncology drugs and has systematically established over 480 tumor models. It can provide comprehensive evaluations for new anti-tumor drugs, including cytotoxic and targeted small molecules, monoclonal and bispecific antibodies, ADCs, and CAR-T/CAR-NK cell therapies.

Through this collaboration, both sides will fully leverage their core technological advantages to build a new ecosystem for oncology drug R&D.

Jaeho Jung, CDO and VP of BIK Therapeutics: “Medicilon’s technical capabilities and experience in oncology are impressive. We look forward to leveraging their innovation to enhance our R&D efficiency. We believe that our joint efforts will bring more breakthrough solutions to the field of precision oncology.”

Jianglin Hu, Co-CEO and CSO of Medicilon: “This partnership is a perfect synergy of BIK Therapeutics’ innovation and Medicilon’s technical platform. Together, we aim to drive the biopharmaceutical industry forward in the era of precision oncology.”